SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

Add RXII Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/26/2017 6:39:05 PM - Followers: 145 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
News News Alert: Statement of Changes in Beneficial Ownership (4) 04/26/2017 06:37:21 PM
#4439   Yes, yes, we know. You should really go The Other Guy 04/26/17 06:39:05 PM
#4438   I'll give credit to Geert as he's been sabaidii2 04/26/17 06:24:30 PM
#4437   Geert makes his regularly scheduled purchase. Must be The Other Guy 04/26/17 04:43:37 PM
#4436   The pre 14A covers the listing issue, vote Full Contact Yoga 04/24/17 10:37:13 AM
#4435   Is RXI going to get a 6-month waiver sabaidii2 04/20/17 12:54:41 PM
#4434   I remember it as the desire of not sabaidii2 04/20/17 12:51:59 PM
#4433   I may be mistaken, but I thought the The Other Guy 04/20/17 12:43:08 PM
#4432   Today's press release says RXI-185 (reducing skin laxity) sabaidii2 04/20/17 10:39:25 AM
#4431   RXI-231: Consumer testing will initiate in May 2017 sabaidii2 04/20/17 09:34:37 AM
#4430   RXi Pharmaceuticals to Present an Update on its The Other Guy 04/20/17 07:22:33 AM
#4429   You are correct. I misspoke. I senderos 04/19/17 07:10:48 PM
#4428   What insider buying? Geert's buys are all under sabaidii2 04/19/17 05:50:13 PM
#4427   IMO, for weeks I have thought there was senderos 04/19/17 05:29:40 PM
#4426   Hmmm, interesting last half hour. Probably another The Other Guy 04/19/17 04:15:28 PM
#4425   Nice comeback this afternoon. senderos 04/19/17 04:01:29 PM
#4423   Short interest increased to 2.337M shares as of The Other Guy 04/19/17 10:07:51 AM
#4422   If there is high short interest, it might sabaidii2 04/19/17 12:36:17 AM
#4421   You and me both on the MirImmune acquisition. The Other Guy 04/18/17 09:53:54 PM
#4420   RXI adds no value to MirImmune acquisition as sabaidii2 04/18/17 05:29:45 PM
#4419   My apologies for recommending RXII. I'm holding out The Other Guy 04/18/17 12:53:54 PM
#4418   I sold out yesterday at a major loss. InternetForumUser 04/18/17 12:02:06 PM
#4417   RXi Pharmaceuticals Announces New Chief Development Officer and The Other Guy 04/18/17 09:09:38 AM
#4416   No idea, but I like it. senderos 04/07/17 02:59:03 PM
#4415   Reversal or something leak out? jonnyvs 04/07/17 02:56:24 PM
#4414   1Q2017 CC Date: Best Guess sabaidii2 04/06/17 04:30:08 AM
#4413   I'm looking at ASTI, SHOM, PURA, PLSB right houseMoney86 04/05/17 10:24:33 PM
#4412   Does RXIIW trade the same as any other stock? sabaidii2 04/05/17 10:22:28 PM
#4411   Does RXIIW trade the same as any other stock? houseMoney86 04/05/17 09:19:29 PM
#4410   Buying the common shares makes sense if you sabaidii2 04/05/17 05:27:14 PM
#4409   Me too... Figures... .77 close lol nah it'll houseMoney86 04/05/17 04:10:05 PM
#4408   OK. I'm back in this one at .79. senderos 04/05/17 01:13:14 PM
#4407   When I originally bought, I thought results would tjguy 04/04/17 02:25:41 AM
#4406   There is lots of discussion regarding the Immuno-oncology sabaidii2 04/02/17 04:25:16 PM
#4405   RXI-231 (skin-lightener) commentary is identical to what was sabaidii2 03/30/17 04:58:54 PM
#4404   My average warrant price is $0.184 sabaidii2 03/30/17 04:23:26 PM
#4403   What price did you buy the warrants? The Other Guy 03/30/17 02:18:48 PM
#4402   Fins out jonnyvs 03/30/17 07:49:06 AM
#4401   While patents are necessary, they are not sufficient. tjguy 03/29/17 07:26:56 PM
#4400   Any clue on how financials will be tomorrow? jonnyvs 03/29/17 07:04:47 PM
#4399   While patents are necessary, they are not sufficient. sabaidii2 03/29/17 06:42:05 PM
#4398   Patent is valuable, however, RX-109 needs approval. In The Other Guy 03/29/17 03:35:01 PM
#4397   now that they were granted patent in japan finwizroger 03/29/17 02:31:57 PM
#4396   The patent news is a positive sign that tjguy 03/29/17 08:59:35 AM
#4395   The patent news is a positive sign that The Other Guy 03/29/17 08:53:56 AM
#4394   The patent news does not seem to be tjguy 03/29/17 08:15:12 AM
#4393   * * $RXII Video Chart 03-28-17 * * ClayTrader 03/28/17 05:16:35 PM
#4392   big money investors will be coming in soon. finwizroger 03/28/17 03:41:45 PM
#4391   big potential here. great chance to go higher finwizroger 03/28/17 03:38:55 PM
#4390   There still remains the minor task of actually sabaidii2 03/28/17 02:49:03 PM
#4389   RXi Pharmaceuticals Granted Patent in Japan for Lead The Other Guy 03/28/17 10:00:02 AM